Diabetic Gastroparesis Drug Pipeline Analysis Report 2024

According to the American Diabetes Association, the prevalence of gastroparesis is approximately 5% in patients with type 1 diabetes and 1% in type 2 diabetes. Gastroparesis is also called delayed gastric emptying, which is a disorder of the digestive tract causing food to remain in the stomach for a longer period than average.

Common medications given to manage the disease include antihistamines, and antibiotics among others. Several clinical trials are ongoing to develop innovative treatments to improve and manage the condition including prokinetic agents or antiemetic agents.

Key Takeaways

• Major companies involved in the diabetic gastroparesis pipeline drugs market include Vanda Pharmaceuticals and CinDome Pharma, Inc., among others.

• Leading drugs currently under pipeline include Metoclopramide Nasal Spray and Tradipitant among others.

• Vanda Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for tradipitant. It is the first drug to be accepted for FDA review for gastroparesis in more than three decades and is expected to become the first to receive approval in four decades.

Report Coverage

The Diabetic Gastroparesis Drug Pipeline Report by Expert Market Research gives comprehensive insights into diabetic gastroparesis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic gastroparesis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic gastroparesis.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to diabetic gastroparesis are covered.

Diabetic Gastroparesis Drug Pipeline Outlook

Diabetic gastroparesis  is a digestive condition that affects how the stomach moves food into the intestines and leads to bloating, nausea, and heartburn. Gastroparesis is a disorder characterized by delayed gastric emptying due to damage to the vagus nerve. The disease is more prevalent in patients having type 1 diabetes than type 2 diabetes. It can be a result of long-term high blood sugar levels which damage the nerves responsible for stomach function. The disease is more common in females than males and is more likely to develop in people who have had surgery around the esophagus, small intestine, or stomach. Moreover, people who have had radiation therapy around the stomach or chest areas are more likely to develop gastroparesis. The symptoms of diabetic gastroparesis include vomiting, nausea, abdominal pain, acid reflux, abdominal bloating, and lack of appetite among others.

The treatment for diabetic gastroparesis varies and includes changing the dosage and timing of insulin, oral medications such as metoclopramide or erythromycin which stimulate the stomach muscles and avoiding drugs that cause delayed gastric emptying among others. Clinical trials for diabetic gastroparesis are focusing on several aspects including new medications, such as the developments of prokinetic agents or antiemetic agents, and combinational therapies. Currently, a clinical trial is investigating the use of oral cannabidiol in the treatment of gastroparesis. The results reported improvement in symptoms as well. The increased number of drug clinical trials for diabetic gastroparesis has impacted the pipeline landscape significantly.

Diabetic Gastroparesis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of diabetic gastroparesis drugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Monoclonal Antibody

• Peptides

• Polymer

• Small Molecule

• Gene Therapy

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral

• Parenteral

• Others

Diabetic Gastroparesis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for diabetic gastroparesis with 32 pipeline drugs in phase II.

Diabetic Gastroparesis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under diabetic gastroparesis pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. Vanda Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a neurokinin 1 receptor (NK-1R) antagonist in development for the treatment of gastroparesis. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for diabetic gastroparesis.

Diabetic Gastroparesis Clinical Trials Assessment – Competitive Dynamics

The EMR report for the diabetic gastroparesis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic gastroparesis clinical trials:

• Vanda Pharmaceuticals

• CinDome Pharma, Inc.

• Evoke Pharma

• Tranzyme, Inc.

• Bird Rock Bio, Inc.

• Liangzhou Wei

• Ironwood Pharmaceuticals, Inc.

• Neurogastrx, Inc.

• Millennium Pharmaceuticals, Inc.

• UCB Pharma

• PTC Therapeutics

• Others

Diabetic Gastroparesis – Pipeline Drugs Profile

Drug- CIN-102

The trial is designed to evaluate whether CIN-102 (deudomperidone) can help reduce the symptoms of diabetic gastroparesis in adult patients. The trial is sponsored by CinDome Pharma, Inc. and is currently under phase II.

Drug: Metoclopramide Nasal Spray

The objective of the study is to evaluate the clinical safety and effectiveness of Metoclopramide Nasal Spray compared to placebo for reducing the symptoms associated with diabetic gastroparesis in adult women. The trial is sponsored by Evoke Pharma and is currently under phase III.

Drug: Tradipitant

Vanda Pharmaceuticals is developing the drug and is currently under phase III. The study is being conducted to evaluate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms associated with gastroparesis.

Reasons To Buy This Report

The Diabetic Gastroparesis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic gastroparesis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within diabetic gastroparesis pipeline insights.

Key Questions Answered in the Diabetic Gastroparesis – Pipeline Assessment Report

• What is the current landscape of diabetic gastroparesis pipeline drugs?

• How many companies are developing diabetic gastroparesis drugs?

• How many phase III and phase IV drugs are currently present in diabetic gastroparesis pipeline drugs?

• Which companies/institutions are leading the diabetic gastroparesis drug development?

• What is the efficacy and safety profile of diabetic gastroparesis pipeline drugs?

• What are the opportunities and challenges present in the diabetic gastroparesis drug pipeline landscape?

• Which company is conducting major trials for diabetic gastroparesis drugs?

• What geographies are covered in diabetic gastroparesis clinical trials?

• What are emerging trends in diabetic gastroparesis clinical trials?

Related Reports

Global Diabetic Gastroparesis Treatment Market

Global Gastrointestinal Stromal Tumour Treatment Market

Global Gastric Ulcer Treatment Market